You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches
Type 2 Inflammation

Partnering With Patients: Scores That Matter in CRSwNP

Learn how partnering with patients and considering the clinical relevance of symptom improvements can improve patient quality of life

/0

Learning objectives

  • Recognize the chronic symptoms in CRSwNP that drive decreases in health-related quality of life
  • Understand how to partner with patients to achieve individual meaningful clinical improvements

Description

Explore this interactive educational tool for guidance on establishing a partnership with patients as it relates to the clinical relevance of symptom improvement and improvements in quality of life of patients with CRSwNP.

Tags
symptomsquality of lifedisease severityguidelinesdisease control
MAT-GLB-2500024 - 1.0 - 01/2025

Related resources

Living With CRSwNP: A Type 2 Inflammatory Airway Disease
Rhinology
expert video

Living With CRSwNP: A Type 2 Inflammatory Airway Disease

Role of Type 2 Inflammation in Skin Barrier Dysfunction in AD
Type 2 Inflammation
expert video

Role of Type 2 Inflammation in Skin Barrier Dysfunction in AD

IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP
Rhinology
expert video

IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP

IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP
Rhinology
expert video

IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP

IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation
Rhinology
expert video

IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation

ADVENT On Air | Loss of Smell in CRSwNP Patients
Rhinology
Podcast

ADVENT On Air | Loss of Smell in CRSwNP Patients

ADVENT On Air | Remission in CRSwNP
Rhinology
Podcast

ADVENT On Air | Remission in CRSwNP

Role of Type 2 Inflammation Across Different Chronic Diseases
Type 2 Inflammation
expert video

Role of Type 2 Inflammation Across Different Chronic Diseases

Trajectories of Type 2 Inflammation in Pediatric Patients
Type 2 Inflammation
expert video

Trajectories of Type 2 Inflammation in Pediatric Patients

Evolving Topics in Type 2 Inflammation
Type 2 Inflammation
expert video

Evolving Topics in Type 2 Inflammation

Connecting the Dots from Type 2 Inflammation to Patient Perspectives
Type 2 Inflammation
expert video

Connecting the Dots from Type 2 Inflammation to Patient Perspectives

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission
Pulmonology
expert video

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission

EAACI 2024 Evolving Perspectives in CRSwNP Patient Care
Pulmonology
expert video

EAACI 2024 Evolving Perspectives in CRSwNP Patient Care

Key Type 2 Cytokines Impact the Skin Microbiome in Atopic Dermatitis
Type 2 Inflammation
expert video

Key Type 2 Cytokines Impact the Skin Microbiome in Atopic Dermatitis

Explore the Global Burden of Pediatric AD (PEDISTAD)
Type 2 Inflammation
interactivity

Explore the Global Burden of Pediatric AD (PEDISTAD)

Type 2 Inflammation in AD Manifestations in Skin and Body
Type 2 Inflammation
expert video

Type 2 Inflammation in AD Manifestations in Skin and Body

Can early intervention modify the course of AD?
Type 2 Inflammation
expert video

Can early intervention modify the course of AD?

Can targeting IL-4 and IL-13 have an effect on relieving the burden of atopic and non-atopic comorbidities in AD?
Type 2 Inflammation
expert video

Can targeting IL-4 and IL-13 have an effect on relieving the burden of atopic and non-atopic comorbidities in AD?

Connecting Type 2 Inflammation to CRSwNP
Rhinology
expert video

Connecting Type 2 Inflammation to CRSwNP

CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients
Rhinology
interactivity

CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients

IRS-ISIAN 2024 | Targeting Type 2 Inflammation: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP
Rhinology
expert video

IRS-ISIAN 2024 | Targeting Type 2 Inflammation: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP

IRS-ISIAN 2024 | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission
Rhinology
expert video

IRS-ISIAN 2024 | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission

IRS-ISIAN 2024 | Guideline Definitions of Control in CRSwNP
Rhinology
expert video

IRS-ISIAN 2024 | Guideline Definitions of Control in CRSwNP

IRS-ISIAN 2024 | The Importance of Understanding Smell Loss and Congestion in CRSwNP
Rhinology
expert video

IRS-ISIAN 2024 | The Importance of Understanding Smell Loss and Congestion in CRSwNP

EAACI 2024 On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control
Pulmonology
expert video

EAACI 2024 On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control

Loss of Smell is a Key Symptom of CRSwNP
Rhinology
Infographic

Loss of Smell is a Key Symptom of CRSwNP

CRSwNP Triathlon: An Interactive Learning Experience
Rhinology
Infographic

CRSwNP Triathlon: An Interactive Learning Experience

Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone
Type 2 Inflammation
expert video

Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone

Impact of Advanced Systemic Therapies on Disease Control in AD
Type 2 Inflammation
expert video

Impact of Advanced Systemic Therapies on Disease Control in AD

Partnering With Patients: Scores That Matter in CRSwNP
Type 2 Inflammation
Infographic

Partnering With Patients: Scores That Matter in CRSwNP

CRSwNP: A Chronic Type 2 Inflammatory Disease
Rhinology
expert video

CRSwNP: A Chronic Type 2 Inflammatory Disease

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: AlgeriaChange country/region